Vasopressin: a new target for the treatment of heart failure

Schrier, 1999, Hormones and hemodynamics in heart failure, N Engl J Med, 341, 577, 10.1056/NEJM199908193410806 1999, HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches, J Card Fail, 5, 357, 10.1016/S1071-9164(99)91340-4 Penit, 1983, Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture, Am J Physiol, 244, E72 Thibonnier, 1994, Molecular cloning, sequencing and functional expression of a cDNA encoding the human V1a vasopressin receptor, J Biol Chem, 269, 3304, 10.1016/S0021-9258(17)41863-1 Nielsen, 1999, Physiology and pathophysiology of renal aquaporins, J Am Soc Nephrol, 10, 647, 10.1681/ASN.V103647 Guyton AC. The kidneys and body fluids. In: Guyton AC, Hall JE, editors. Textbook of Medical Physiology. Philadelphia: WB Saunders Company; 1996. p. 308–72 Goldsmith, 1987, Vasopressin as vasopressor, Am J Med, 82, 1213, 10.1016/0002-9343(87)90228-2 Ebert, 1986, Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man, J Clin Invest, 77, 1136, 10.1172/JCI112413 Sampey, 1999, Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats, Am J Physiol, 276, R872 Khayyal, 1985, Effects of vasopressin on the coronary circulation, Am J Physiol, 248, H516 Walker, 1988, Direct cardiac effects of vasopressin, Am J Physiol, 255, H261 Fujisawa, 1999, On the inotropic actions of arginine vasopressin in ventricular muscle of the guinea pig heart, Jpn J Pharmacol, 81, 309, 10.1254/jjp.81.309 Goldsmith, 1983, Increased plasma arginine vasopressin levels in patients with congestive heart failure, J Am Coll Cardiol, 1, 1385, 10.1016/S0735-1097(83)80040-0 Szatalowicz, 1981, Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure, N Engl J Med, 305, 263, 10.1056/NEJM198107303050506 Francis, 1990, Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure, Circulation, 82, 1724, 10.1161/01.CIR.82.5.1724 Goldsmith, 1986, Arginine vasopressin and the renal response to water loading in congestive heart failure, Am J Cardiol, 58, 295, 10.1016/0002-9149(86)90065-2 Schrier, 1998, Recent advances in the understanding of water metabolism in heart failure, Adv Exp Med Biol, 449, 415, 10.1007/978-1-4615-4871-3_53 Xu, 1997, Upregulation of aquaporin-2 water channel expression in chronic heart failure rat, J Clin Invest, 99, 1500, 10.1172/JCI119312 Chin, 1996, Correlates of major complications or death in patients admitted to the hospital with congestive heart failure, Arch Intern Med, 156, 1814, 10.1001/archinte.1996.00440150068007 Goldsmith, 1986, Hemodynamic effects of infused arginine vasopressin in congestive heart failure, J Am Coll Cardiol, 8, 779, 10.1016/S0735-1097(86)80417-X Tahara, 1998, Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte, Cardiovasc Res, 38, 198, 10.1016/S0008-6363(97)00324-6 Nakamura, 2000, Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor, Eur J Pharmacol, 391, 39, 10.1016/S0014-2999(99)00775-X Fukuzawa, 1999, Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor, Mol Cell Biochem, 195, 93, 10.1023/A:1006980517557 Bird, 2001, Significant reduction in cardiac fibrosis and hypertrophy in spontaneously hypertensive rats (SHR) treated with a V1a receptor antagonist, Circulation, 104, 186 van der Bent, 1994, i and protein kinase C in vasopressin-induced prostacyclin and ANP release in rat cardiomyocytes, Am J Physiol, 266, H597 Shoji, 1986, Role of intracerebral angiotensin receptors in the regulation of vasopressin release and the cardiovascular system, Neuroendocrinology, 43, 239, 10.1159/000124532 Yamamoto, 1992, Central effects of endothelin-1 on vasopressin release, blood pressure, and renal solute excretion, Am J Physiol, 262, E856 Creager, 1986, Contribution of vasopressin to vasoconstriction in patients with congestive heart failure, J Am Coll Cardiol, 7, 758, 10.1016/S0735-1097(86)80333-3 Clair, 2000, Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure, J Pharmacol Exp Ther, 293, 852 Nicod, 1985, Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure, Am J Cardiol, 55, 1043, 10.1016/0002-9149(85)90743-X Ohnishi, 1995, Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men, J Pharmacol Exp Ther, 272, 546 Burrell, 1998, Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat, Am J Physiol, 275, H176 Yamamura, 1998, OPC-41061, a highly potent human vasopressin V2-receptor antagonist, J Pharmacol Exp Ther, 287, 860 Hirano, 2000, Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats, J Pharmacol Exp Ther, 292, 288 Naitoh, 1994, Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs, Am J Physiol, 267, H2245 Serradeil-Le Gal, 1996, Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist, J Clin Invest, 98, 2729, 10.1172/JCI119098 Gheorghiade, 2000, Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure, Circulation, 102, 592 Gheorghiade, 2002, Vasopressin receptor blockade with tolvaptan in chronic heart failure, J Am Coll Cardiol, 39, 171A, 10.1016/S0735-1097(02)80757-4 Udelson, 2002, Vasopressin receptor blockade in patients with congestive heart failure, J Am Coll Cardiol, 39, 156A, 10.1016/S0735-1097(02)80688-X Gheorghiade, 2001, Vasopressin V2 receptor blockade versus fluid restriction in the treatment of hyponatremia, Circulation, 104, 438 Chan, 1998, VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist, Adv Exp Med Biol, 449, 439, 10.1007/978-1-4615-4871-3_55 Abraham, 1997, Effects of an oral, nonpeptide, selective V2 receptor vasopressin antagonist in patients with chronic heart failure, J Am Coll Cardiol, 29, 169A Martin, 1999, Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure, J Am Soc Nephrol, 10, 2165, 10.1681/ASN.V10102165 Serradeil-Le Gal, 2001, An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist, Cardiovasc Drug Rev, 19, 201, 10.1111/j.1527-3466.2001.tb00065.x Tahara, 1997, Pharmacological profile of YM087, a novel potent vasopressin V1A and V2 receptor antagonist, in vitro and in vivo, J Pharmacol Exp Ther, 282, 301 Yatsu, 1997, Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs, Eur J Pharmacol, 321, 225, 10.1016/S0014-2999(96)00940-5 Yatsu, 1999, Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure, Eur J Pharmacol, 376, 239, 10.1016/S0014-2999(99)00379-9 Burnier, 1999, Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects, Eur J Clin Pharmacol, 55, 633, 10.1007/s002280050685 Udelson, 2001, Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure, Circulation, 104, 2417, 10.1161/hc4501.099313 Painchaud, 2000, Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure, Circulation, 102, 535 Smith, 2001, Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients, J Am Coll Cardiol, 37, 172